GRPH News and Press, Graphite Bio Inc. From 08/11/22

Graphite Bio press release ( NASDAQ: GRPH ): Q2 GAAP EPS of -$0.48 beats by $0.01 . cash, cash equivalents and investments in marketable securities totaled $328.3 million. For further details see: Graphite Bio GAAP EPS of -$0.48 beats by $0.01

Dosed first patient with nulabeglogene autogedtemcel (nula-cel), formerly known as GPH101, in Phase 1/2 CEDAR clinical trial in people with sickle cell disease; initial proof-of-concept data now anticipated in mid-2023 Presented preclinical gene replacement data for GPH102 in ...

Graphite Bio ( NASDAQ: GRPH ) is trading 2.1% higher after the company said it had finished dosing the first patient with its drug, GPH101, now called nulabeglogene autogedtemcel, in the company’s Phase 1/2 trial to treat people with sickle cell diseas...

GPH101, now called nulabeglogene autogedtemcel (nula-cel), designed to directly correct the genetic mutation that causes sickle cell disease Initial proof-of-concept data from Phase 1/2 CEDAR trial anticipated in mid-2023 Graphite Bio, Inc. (Nasdaq: GRPH), a clinical...

Over the past seven weeks, I have suggested that healthcare stocks, and specifically biopharmaceuticals, had begun to bottom. I expected the process to be rocky with an upside bias. As I spoke with sell side analysts, buy side investors and individuals, I found support for my thinking...

Clinical-stage biotech Graphite Bio (NASDAQ:GRPH) traded sharply higher on Friday after BMO Capital Markets initiated its coverage with an Outperform rating and a $12 per share target implying a premium of ~461% to the last close. The analyst Kostas Biliouris highlights the company’s g...

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will pre...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

Shares of Graphite Bio are down some 85% from their June 2021 IPO pricing, as its first-ever clinical trial for the treatment of sickle cell disease experienced a six-month delay. The company’s potentially curative technology builds on CRISPR Therapeutics by pasting a DNA templ...

The following slide deck was published by Graphite Bio, Inc. in conjunction with this event. For further details see: Graphite Bio Investor Presentation - Slideshow